Clinical data have already confirmed the presence of four immune subtypes of GBM with significant differences in the prognosis and distribution of immune checkpoints, and we believe that identifying these will provide more clinical treatment options with immunotherapy already approved in other cancers (particularly blocking the PD-1/PD-L1 axis) for subgroups of GBM patients [93]. This evidence concerns the gene CD274 and glioblastoma.